Bryan Schwieters, MD
Psychiatry · Eagan, MNNPI 1841243631
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,880 of the $6,636 with a category attached, or 88.6%. AbbVie accounts for 90.1% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2021 at $5,356 and has fallen 97.4% since, to $138 in 2025. Among psychiatry clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $88.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Neurocrine Biosciences, Inc.$112
- Corium, LLC$63
- Neuronetics, Inc.$58
- Almatica Pharma LLC$55
- Otsuka America Pharmaceutical, Inc.$48
- plus $322 from 13 others
What the payments were for
- Speaking & faculty fees$5,88089%
- Food & beverage$75611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $5,977 |
| Neurocrine Biosciences, Inc. | 9 | $112 |
| Corium, LLC | 6 | $63 |
| Neuronetics, Inc. | 3 | $58 |
| Almatica Pharma LLC | 4 | $55 |
| Otsuka America Pharmaceutical, Inc. | 4 | $48 |
| Alkermes, Inc. | 3 | $44 |
| Vanda Pharmaceuticals Inc. | 3 | $43 |
| Teva Pharmaceuticals USA, Inc. | 3 | $42 |
| Tris Pharma Inc | 2 | $33 |
| Axsome Therapeutics, Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Tempus AI, Inc | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Brainsway USA Inc | 1 | $13 |
| Indivior Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$5,880
How this compares
$6,636 in reported general payments places this provider in the 95th percentile of 552 psychiatry providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 17 | $48,700 |
| TrintellixVortioxetine Hydrobromide | 58 | $34,016 |
| RexultiBrexpiprazole | 16 | $22,468 |
| VyvanseLisdexamfetamine Dimesylate | 46 | $21,128 |
| Aripiprazole | 155 | $13,192 |
| Lisdexamfetamine Dimesylate | 60 | $12,453 |
| Clozapine OdtClozapine | 13 | $7,871 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 39 | $7,825 |
| AbilifyAripiprazole | 12 | $7,731 |
| MovantikNaloxegol Oxalate | 17 | $6,896 |
| Lurasidone Hcl | 54 | $5,887 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 65 | $5,459 |
| SeroquelQuetiapine Fumarate | 11 | $5,159 |
| Dextroamphetamine Sulfate | 87 | $4,498 |
| Asenapine Maleate | 12 | $4,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $48 | $71,16833 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $26 | $55,143104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 552 psychiatry providers in Minnesota.
Other psychiatry in Eagan
- Sujit VarmaEdina$581K
- Michael FarnsworthMankato$548K
- Danielle Magness-WellmannMankato$232K
- Craig VineSt Paul$136K
- Thomas WinegardenChanhassen$55K
- John LuehrMinnetonka$41K
- Walter RushSaint Paul$41K
- John SimonMinneapolis$32K
- Ziad NahasMinneapolis$32K
- Sophia VinogradovMinneapolis$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.